ArticleScientific data2026
De-novo assembly of 82 bacterial genomes using Nanopore sequencing and prediction of biosynthetic capacity.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- De-novo assembly of 82 bacterial genomes using Nanopore sequencing and prediction of biosynthetic capacity.Scientific data · 2026Article
- Culture-Dependent and Molecular Characterization of Bacteria Associated with Banana Fruits in Puerto Rico.microPublication biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Historically, antibiotic development has been driven by research into secondary metabolism which is responsible for the biosynthesis of so-called natural products. This research has been revolutionized by our growing capacity to rapidly generate and analyze prokaryotic genome sequences, facilitating the identification of biosynthetic gene clusters (BGCs) involved in secondary metabolism. We present the genomic analysis of 82 bacterial isolates from our collection, covering a broad taxonomic spectrum. The bulk of analyzed isolates belong to the actinobacterial class of Actinomycetes, known for their remarkable ability to generate antimicrobial compounds with diverse chemistries. Whole genome sequencing was performed using the Oxford Nanopore technology and the majority of assembled sequences exhibit over 90% gene completeness, enabling reliable functional annotation. Genome mining analyses revealed variability in BGC content across different phyla, confirming isolates in the Streptomyces genus as preeminent producers of secondary metabolites. Utilization of the current dataset holds potential not only for the elucidation of the bacterial biosynthetic machinery, but also for phylogenetic comparison and biotechnological exploitation of the isolates under study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.